Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).
Lauren Veltri(West Virginia University), Aaron Cumpston(West Virginia University Hospitals), Alexandra Shillingburg(West Virginia University), Abraham S. Kanate(HonorHealth), Michael Craig(Edith Cowan University), Brandi Anders(West Virginia University)
Cited by 0
Related Papers
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
|Blood|2015|273
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
|Blood|2017|247
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183